-
The Tumor Environment in Peritoneal Carcinomatosis and Malignant Pleural Effusions: Implications for Therapy -
Integrating Molecular Phenotyping into Treatment Algorithms for Advanced Oestrogen Receptor-Positive Breast Cancer -
Dermal Mitoses Correlate with Surgical Burden in Lentigo Maligna Melanoma: PRAME for Margin Assessment
Journal Description
Cancers
Cancers
is a peer-reviewed, open access journal of oncology, published semimonthly online by MDPI. The Irish Association for Cancer Research (IACR), Spanish Association for Cancer Research (ASEICA), Biomedical Research Centre (CIBM), British Neuro-Oncology Society (BNOS) and Spanish Group for Cancer Immuno-Biotherapy (GÉTICA) are affiliated with Cancers and their members receive a discount on the article processing charges.
- Open Access— free for readers, with article processing charges (APC) paid by authors or their institutions.
- High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
- Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)
- Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 20.3 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).
- Recognition of Reviewers: reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.
- Sections: published in 18 topical sections.
- Companion journals for Cancers include: Radiation and Onco.
- Journal Clusters of Oncology: Cancers, Current Oncology, Onco and Targets.
Impact Factor:
4.4 (2024);
5-Year Impact Factor:
4.8 (2024)
Latest Articles
From Slide to Insight: The Emerging Alliance of Digital Pathology and AI in Melanoma Diagnostics
Cancers 2025, 17(22), 3696; https://doi.org/10.3390/cancers17223696 (registering DOI) - 18 Nov 2025
Abstract
Background: Cutaneous melanoma (CM) poses significant diagnostic challenges due to its biological heterogeneity and the subjective interpretation of histopathologic criteria. While early and accurate diagnosis remains critical for patient outcomes, conventional pathology is limited by interobserver variability and diagnostic ambiguity, especially in borderline
[...] Read more.
Background: Cutaneous melanoma (CM) poses significant diagnostic challenges due to its biological heterogeneity and the subjective interpretation of histopathologic criteria. While early and accurate diagnosis remains critical for patient outcomes, conventional pathology is limited by interobserver variability and diagnostic ambiguity, especially in borderline lesions. Objective: This narrative review explores the integration of digital pathology (DP) and artificial intelligence (AI)—including deep learning (DL), machine learning (ML), and interpretable models—into the histopathologic workflow for CM diagnosis. Methods: We systematically searched PubMed, Scopus, and Web of Science (2013–2025) for studies using whole slide imaging (WSI) and AI to assist melanoma diagnosis. We categorized findings across five domains: WSI-based classification models, feature extraction (e.g., mitoses, ulceration), spatial modeling and TIL analysis, molecular prediction (e.g., BRAF mutation), and interpretable pipelines based on nuclei morphology. Results: We included 87 studies with diverse AI methodologies. Convolutional neural networks (CNNs) achieved diagnostic accuracy comparable to expert dermatopathologists. U-Net and Mask R-CNN models enabled robust detection of critical histologic features, while nuclei-level analyses offered explainable classification strategies. Spatial and morphometric modeling allowed quantification of tumor–immune interactions, and select models inferred molecular alterations directly from H&E slides. However, generalizability remains limited due to small, homogeneous datasets and lack of external validation. Conclusions: AI-enhanced digital pathology holds transformative potential in CM diagnosis, offering accuracy, reproducibility, and interpretability. Yet, clinical integration requires multicentric validation, standardized protocols, and attention to workflow, ethical, and medico-legal challenges. Future developments, including multimodal AI and integration into molecular tumor boards, may redefine diagnostic precision in melanoma.
Full article
(This article belongs to the Special Issue Novel Research on the Diagnosis and Treatment of Melanoma)
Open AccessArticle
Hepatitis C Virus Infection Associated with Oral Potentially Malignant Disorder, Oral Cancer, and Liver Diseases: A Community-Based Cross-Sectional Study
by
Donlagon Jumparway, Chen-Yang Hsu, Amy Ming-Fang Yen, Ting-Yu Lin, Saman Warnakulasuriya, Tony Hsiu-Hsi Chen, Dih-Ling Luh, Chiu-Wen Su, Pongdech Sarakarn, Yen-Po Yeh and Sam Li-Sheng Chen
Cancers 2025, 17(22), 3695; https://doi.org/10.3390/cancers17223695 (registering DOI) - 18 Nov 2025
Abstract
Background/Objectives: While smoking, areca nut chewing, and alcohol are established risk factors, Hepatitis C virus (HCV) infection has emerged as a potential risk for oral neoplasia. This study explores any association of HCV infection with oral potentially malignant disorder (OPMD) and oral cancer,
[...] Read more.
Background/Objectives: While smoking, areca nut chewing, and alcohol are established risk factors, Hepatitis C virus (HCV) infection has emerged as a potential risk for oral neoplasia. This study explores any association of HCV infection with oral potentially malignant disorder (OPMD) and oral cancer, following adjustment for HCV-related liver disease in a large screening cohort. Methods: Data from 37,720 participants in the Changhua Community-Based Integrated Screening Program (2005–2014) with smoking or areca nut use history were analyzed. OPMD and cirrhosis were identified at screening, while oral and liver cancers were diagnosed during follow-up. Information on demographics, lifestyle, and clinical factors, including chronic and active HCV infection, was collected. Multinomial logistic regression was used to assess associations between HCV status and disease outcomes. Results: The prevalence of hepatitis C viremia was higher in the OPMD group (4.4%) and oral cancer group (3.3%) compared to the screen-negative group (2.7%), and highest in the cirrhosis/liver cancer group (23.3%). The odds ratios of OPMD and oral cancer were 1.59 (95% CI: 1.20–2.01) and 1.22 (95% CI: 0.67–2.23), respectively, in subjects with hepatitis C viremia compared to those without. After adjusting for confounding factors, individuals with hepatitis C viremia were at increased risk of OPMD by 50% (aOR = 1.50; 95% CI: 1.17–1.92) but not a statistically significant elevated risk for oral cancer (aOR = 1.09; 95% CI: 0.59–2.01), which was possibly attenuated due to HCV-related liver disease (aOR = 11.59; 95% CI: 8.33–16.13). Conclusions: HCV infection may act as an early risk factor for OPMD, though its progression to oral cancer may occur alongside the risk of HCV-related liver diseases. Including HCV status in screening may aid early detection and secondary prevention of oral cancer in high-risk groups.
Full article
(This article belongs to the Section Infectious Agents and Cancer)
►▼
Show Figures

Figure 1
Open AccessArticle
Prognosis Prediction Model After Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Study (OS-HBP-2)
by
Kosei Takagi, Ryuichi Yoshida, Kazuya Yasui, Masayoshi Hioki, Takehiro Okabayashi, Toru Kojima, Yoshikatsu Endo, Daisuke Nobuoka, Kenta Sui, Masaru Inagaki, Susumu Shinoura, Masashi Kimura, Tatsuo Matsuda, Hideki Aoki and Toshiyoshi Fujiwara
Cancers 2025, 17(22), 3694; https://doi.org/10.3390/cancers17223694 (registering DOI) - 18 Nov 2025
Abstract
Background/Objectives: Upfront surgery (UFS) remains the standard treatment for patients with resectable pancreatic ductal adenocarcinoma (PDAC). We aimed to investigate the prognostic factors for survival after UFS in patients with resectable PDAC and to develop a prognostic prediction model. Methods: This
[...] Read more.
Background/Objectives: Upfront surgery (UFS) remains the standard treatment for patients with resectable pancreatic ductal adenocarcinoma (PDAC). We aimed to investigate the prognostic factors for survival after UFS in patients with resectable PDAC and to develop a prognostic prediction model. Methods: This multicenter, retrospective study included 603 patients who underwent UFS for resectable PDAC between January 2013 and December 2017. Univariate and multivariate analyses were performed to identify prognostic factors for overall survival (OS). We constructed a prognostic prediction model for OS after UFS. An internal validation was performed to evaluate the discriminative performance of the model. Results: The 1-, 3-, and 5-year OS rates were 83.7%, 48.2%, and 37.5%, respectively. The Cox proportional hazards model showed that tumor size > 2 cm (hazard ratio [HR] 1.50, p = 0.001); tumor contact with the portal and superior mesenteric veins of ≤180° (HR 1.47, p = 0.003); carbohydrate antigen 19-9 levels of 40 to 500 U/mL (HR 1.59, p = 0.002) and ≥500 U/mL (HR 2.16, p < 0.001); and a modified Glasgow Prognostic Score of two (HR 1.56, p = 0.038) were predictors associated with OS. The prognostic prediction model for 5-year OS demonstrated an area under the curve of 0.68. The calibration plots indicate a concordance index of 0.63. Conclusions: We identified the preoperative prognostic factors for OS and developed a prognostic prediction model to estimate OS in patients undergoing UFS for resectable PDAC. Our model may be useful and internally validated for predicting OS.
Full article
(This article belongs to the Section Clinical Research of Cancer)
►▼
Show Figures

Figure 1
Open AccessArticle
VHL Gene Restoration Supports RCC Reprogramming to iPSCs but Does Not Ensure Line Stability
by
Zsuzsanna Lichner, Yasaman Shamshirgaran, Katarzyna Pieczonka, Anna Jonebring, Mark Kibschull, Oksana Shynlova, Jalna Meens, Raymond H. Kim, Laurie Ailles, Bilada Bilican, Ryan Hicks and Ian M. Rogers
Cancers 2025, 17(22), 3693; https://doi.org/10.3390/cancers17223693 - 18 Nov 2025
Abstract
Background: Modeling precancerous stages holds the promise to understand early transformation events, thereby offering the potential for personalized, targeted treatment. Because cancer hijacks developmental pathways, precancerous stages could potentially be modeled by reprogramming cancer cells to an induced pluripotent stem cell state and
[...] Read more.
Background: Modeling precancerous stages holds the promise to understand early transformation events, thereby offering the potential for personalized, targeted treatment. Because cancer hijacks developmental pathways, precancerous stages could potentially be modeled by reprogramming cancer cells to an induced pluripotent stem cell state and subsequently differentiating them to the target organs using organoid models. Methods: We attempted reprogramming of patient-derived clear cell renal cell carcinoma (ccRCC) cell lines and adjacent normal renal epithelial cell lines using lentivirus or episomal reprogramming vectors. Results: The cancer cells failed to reprogram while the adjacent normal cells reprogrammed with high efficiency. The von Hippel–Lindau factor (VHL) gene was re-expressed in ccRCC cells in an attempt to restore the wild-type phenotype and restore reprogramming. The VHL gene is the major tumor suppressor in ccRCC pathogenesis and a conductor of oxidative-glycolytic glucose metabolism. While its re-expression did restore the epithelial phenotype and oxidative regulation of ccRCC cells, they still failed to stably reprogram. With an optimized reprogramming workflow, VHL-corrected ccRCC cells generate NANOG+ cells; however, they remained dependent on the ectopic expression of the reprogramming factors. Conclusions: We concluded that while VHL expression is necessary for cellular reprogramming of ccRCC cells, other genetic lesions in the ccRCC cells could be preventing the stabilization of the pluripotent state.
Full article
(This article belongs to the Section Methods and Technologies Development)
►▼
Show Figures

Figure 1
Open AccessReview
Circulating Tumor DNA (ctDNA) in Gastroesophageal Adenocarcinoma (GEA): Evidence and Emerging Applications
by
Oudai Sahwan, Lin Batha, Fares Jamal and Mohamad Bassam Sonbol
Cancers 2025, 17(22), 3692; https://doi.org/10.3390/cancers17223692 - 18 Nov 2025
Abstract
The role of circulating tumor DNA (ctDNA) in gastroesophageal adenocarcinoma (GEA) has expanded in recent years. In resectable disease, postoperative ctDNA is able to detect patients at highest risk of recurrence months before scans. Tumor-informed assays provide the best sensitivity and emerging methylation
[...] Read more.
The role of circulating tumor DNA (ctDNA) in gastroesophageal adenocarcinoma (GEA) has expanded in recent years. In resectable disease, postoperative ctDNA is able to detect patients at highest risk of recurrence months before scans. Tumor-informed assays provide the best sensitivity and emerging methylation assays are useful when tissue is scarce. In metastatic GEA, baseline ctDNA burden correlates with prognosis, and a decrease in ctDNA level after treatment initiation reflects therapeutic response. It can also uncover actionable targets, including ERBB2, FGFR2, and MSI-H, and detect resistance that can arise after starting treatment. Limitations include variable assay performance, low shedding in some tumors, clonal hematopoiesis confounding, and a lack of randomized data showing that ctDNA-guided changes improve outcomes. Ongoing trials are testing MRD-guided escalation/de-escalation and ctDNA-directed biomarker therapy. In this review, we evaluate the role of ctDNA in GEA cancers over recent years.
Full article
(This article belongs to the Special Issue Cell-Free DNA as Prognostic and Predictive Biomarker in Solid Cancers (2nd Edition))
►▼
Show Figures

Figure 1
Open AccessArticle
Prompt-Driven Multimodal Segmentation with Dynamic Fusion for Adaptive and Robust Medical Imaging with Applications to Cancer Diagnosis
by
Shatha Abed Alsaedi, Hossam Magdy Balaha, Mohamed Farsi, Majed Alwateer, Moustafa M. Aboelnaga, Mohamed Shehata, Mahmoud Badawy and Mostafa A. Elhosseini
Cancers 2025, 17(22), 3691; https://doi.org/10.3390/cancers17223691 - 18 Nov 2025
Abstract
Background/Objectives: Medical image segmentation is a crucial task for diagnosis, treatment planning, and monitoring of cancer; however, it remains one of the toughest nuts to crack for Artificial Intelligence (AI)-based clinical applications. Deep-learning models have shown near-perfect results for narrow tasks such as
[...] Read more.
Background/Objectives: Medical image segmentation is a crucial task for diagnosis, treatment planning, and monitoring of cancer; however, it remains one of the toughest nuts to crack for Artificial Intelligence (AI)-based clinical applications. Deep-learning models have shown near-perfect results for narrow tasks such as single-organ Computed Tomography (CT) segmentation. Still, they fail to deliver under practicality, in which cross-modality robustness and multi-organ delineation are essential (e.g., liver Dice dropping to 0.88 ± 0.15 in combined CT-MR scenarios). That fragility exposes two structural gaps: (i) rigid task-specific architectures, which are not flexible enough to adapt to various clinical instructions, and (ii) the assumption that a universal loss function is best in all cancer imaging applications. Methods: A novel multimodal segmentation framework is proposed that combines natural language prompts and high-fidelity imaging features through Feature-wise Linear Modulation (FiLM) and Conditional Batch Normalization, enabling a single model to adapt dynamically across modalities, organs, and pathologies. Unlike preceding systems, the proposed approach is prompt-driven, context-aware, and end-to-end trainable to ensure alignment between computational adaptability and clinical decision-making. Results: Extensive evaluation on the Brain Tumor Dataset (cancer-relevant neuroimaging) and the CHAOS multi-organ challenge demonstrates two key insights: (1) while Dice loss remains optimal for single-organ tasks, (2) Jaccard (IoU) loss outperforms when multi-organ, cross-modality divides cancer segmentation boundaries. Empirical evidence has thus been offered that optimality of a loss function is task- and context-dependent and not universal. Conclusions: The design framework’s principles directly address what is documented in workflow requirements and display capabilities that may connect algorithmic innovation with clinical utility once validated through prospective clinical trials.
Full article
(This article belongs to the Special Issue Deep Learning and Radiomics for Cancer Diagnosis, Staging, and Treatment Response)
►▼
Show Figures

Figure 1
Open AccessArticle
Take a Breather—Physiological Correlates of a Conscious Connected Breathing Session in a Trained Group of Breast Cancer Patients
by
Alicja Heyda, Agnieszka Gdowicz-Kłosok, Magdalena Bugowska, Marcela Krzempek, Kinga Dębiec, Jolanta Mrochem-Kwarciak and Krzysztof Składowski
Cancers 2025, 17(22), 3690; https://doi.org/10.3390/cancers17223690 - 18 Nov 2025
Abstract
Introduction/Goal: Stress and negative emotions have been shown to exert a substantial impact on cancer patients, affecting their ability to adapt to therapy and the overall effectiveness. Elevated cortisol levels, a stress-induced hormone, have been shown to suppress immune system function, potentially reducing
[...] Read more.
Introduction/Goal: Stress and negative emotions have been shown to exert a substantial impact on cancer patients, affecting their ability to adapt to therapy and the overall effectiveness. Elevated cortisol levels, a stress-induced hormone, have been shown to suppress immune system function, potentially reducing the body’s capacity to combat cancer cells. On the contrary, prolactin, a hormone that stimulates the immune system, has shown potential in this context but requires further study. The objective of this study was to investigate the acute physiological changes that occur during a single Conscious Connected Breathing (CCB) session, as part of a larger investigation on Integrative Breathwork Psychotherapy (IBP), a novel integrative psychosomatic intervention designed to improve psychosomatic and immune status in cancer patients. Methods: The project involved 93 breast cancer patients hospitalized for postoperative radiotherapy who participated in a ten-session IBP program. Fifty-six patients agreed to participate (response rate: 60%). During the experiment, 8 patients were excluded from the analysis. IBP consisted of small group sessions (up to six participants) conducted three times weekly. Each session included 45 min of CCB—defined as rhythmic circular nasal breathing at a depth exceeding resting tidal volume, without breath-holding, performed in a state of mindful acceptance—followed by 15 min of free emotional expression (verbal articulation of emerging feelings and sensations). This was a within-subject pre-post design: physiological measurements were obtained immediately before and 30 min into the tenth session (when participants had achieved technical proficiency) in all participants, who served as their own controls. Outcome measures included: arterialized capillary blood gas parameters (pH, pCO2, pO2, ctO2, COHb, HHb, cH+), serum cortisol and prolactin concentrations, and immunoglobulin A (IgA). Results: During the CCB session, blood gas analysis revealed significant changes consistent with mild respiratory alkalosis: decreases in pCO2 (p = 0.003), pO2 (p < 0.001), cH+ (p < 0.001), ctO2 (p < 0.001), COHb (p = 0.03), and HHb (p = 0.004), alongside an increase in pH (p < 0.001). Concurrently, prolactin levels increased significantly (p < 0.001), while cortisol (p < 0.001) and IgA (p < 0.001) decreased. Conclusions: This study is the first to analyze acute changes in capillary blood gas parameters and neuroendocrine balance during Conscious Connected Breathing sessions in cancer patients, revealing measurable immunostimulatory and stress-modulatory effects. The observed shift toward respiratory alkalosis, combined with increased prolactin and decreased cortisol, suggests that CCB may facilitate favorable neuroendocrine-immune interactions. These findings support the potential of breathwork as a complementary therapy for cancer patients. Further research is needed to explore underlying mechanisms and assess long-term psychological and immunological impacts.
Full article
(This article belongs to the Special Issue Empowering Cancer Survivors: A Comprehensive Approach to Supportive Care Through Pharmacological and Non-Pharmacological Approaches Including Exercise, Physical Activity and Nutrition)
►▼
Show Figures

Figure 1
Open AccessSystematic Review
Optimizing Preoperative Anemia in Non-Metastatic Colorectal Cancer: A Systematic Review on Surgical Recovery and Outcomes
by
Sophia Tsokkou, Ioannis Konstantinidis, Menelaos Papakonstantinou, Paraskevi Chatzikomnitsa, Areti Danai Gkaitatzi, Eftychia Liampou, Antonios Fantakis, Georgia Kolympa, Evdokia Toutziari, Dimitrios Alexandrou, Dimitrios Giakoustidis, Petros Bangeas, Vasileios N. Papadopoulos and Alexandros Giakoustidis
Cancers 2025, 17(22), 3689; https://doi.org/10.3390/cancers17223689 - 18 Nov 2025
Abstract
Background/Objectives: Colorectal cancer (CRC) is among the most commonly reported malignancies globally, taking the third place in incidence among males as well as the second among females, with over 1.9 million new cases and 935,000 deaths estimated worldwide in 2020. One of the
[...] Read more.
Background/Objectives: Colorectal cancer (CRC) is among the most commonly reported malignancies globally, taking the third place in incidence among males as well as the second among females, with over 1.9 million new cases and 935,000 deaths estimated worldwide in 2020. One of the most common and clinically significant comorbidities in patients undergoing CRC surgery is preoperative anemia, with reported prevalence ranging from 23% to over 60% depending on the population and diagnostic criteria used. The objective of the current study is to systematically evaluate the current body of evidence on preoperative anemia management in adults undergoing surgery for non-metastatic CRC. This review aims to assess the clinical impact of different iron supplementation strategies, particularly IV versus oral iron in pre-operative hematologic optimization, transfusion requirements, postoperative complications, and recovery outcomes. Methods: The current systematic review was conducted based on the PRISMA for Systematic Reviews and Meta-analysis checklist. The study has been registered to PROSPERO with the ID CRD420251113455. Results: Across all studies, IV iron and erythropoiesis-stimulating agents emerged as safe and more efficient alternatives to iron per os, especially when initiated at least two weeks before surgery. Thus, highlighting the clinical value of proactive anemia management as a cornerstone of surgical prehabilitation, potentially reducing transfusion burden and improving recovery outcomes for CRC patients. Conclusions: It is observed that IV iron therapy offers a more effective strategy than per os supplementation for correcting preoperative anemia in non-metastatic colorectal cancer patients. Their hematologic benefits enhance surgical readiness and reduce postoperative intervention needs. Thus, supporting the integration of IV iron into preoperative optimization protocols.
Full article
(This article belongs to the Special Issue The Surgical Management of Colorectal Cancer)
►▼
Show Figures

Graphical abstract
Open AccessArticle
Long-Term Risk of Pneumonia Among Gastric Cancer Survivors: A Nationwide Population-Based Cohort Study
by
Kyeong Min Han, Ho Suk Kang, Joo-Hee Kim, Hyo Geun Choi, Dae Myoung Yoo, Nan Young Kim, Ha Young Park and Mi Jung Kwon
Cancers 2025, 17(22), 3688; https://doi.org/10.3390/cancers17223688 - 18 Nov 2025
Abstract
Background/Objectives: Gastric cancer (GC) remains a major global health burden, but its long-term association with pneumonia risk has not been comprehensively investigated. This study aimed to evaluate the long-term risk of pneumonia among GC survivors using a nationwide Korean cohort, focusing on chronic
[...] Read more.
Background/Objectives: Gastric cancer (GC) remains a major global health burden, but its long-term association with pneumonia risk has not been comprehensively investigated. This study aimed to evaluate the long-term risk of pneumonia among GC survivors using a nationwide Korean cohort, focusing on chronic post-cancer susceptibility rather than perioperative or treatment-related complications. Methods: We conducted a nationwide, population-based cohort study using the Korean National Health Insurance Service database, including 9212 GC patients and 36,848 age-, sex-, income-, and region-matched controls (1:4 ratio). Participants were followed for up to 17 years. Propensity score overlap weighting was applied to minimize confounding, achieving exact covariate balance and optimal precision, with standardized differences used to confirm balance. Adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for pneumonia were estimated via Cox proportional hazards models. Results: During follow-up from 2002–2003 through 2019 (maximum 17 years), GC showed a significant relationship with increased risk of pneumonia (aHR 1.06; 95% CI: 1.01–1.11; p = 0.014). Subgroup analyses revealed higher risks among men, socioeconomically disadvantaged individuals, urban residents, and unexpectedly, patients without comorbidities. Conclusions: This large nationwide cohort study demonstrated that GC may be linked to a slightly elevated long-term risk of pneumonia, varying across demographic and clinical subgroups. These findings underscore the need for continued respiratory health monitoring in GC survivors while acknowledging that the observed association may be influenced by underlying comorbidities and survivorship factors.
Full article
(This article belongs to the Section Cancer Informatics and Big Data)
►▼
Show Figures

Figure 1
Open AccessArticle
SCODA: A Low-Cost Prehabilitation Strategy to Improve Outcomes After Cytoreductive Surgery in a Low-Resource Setting
by
Amine Souadka, Lina Alami, Zakaria Elmouatassim, Oumayma Lahnaoui, Yassine El Bouazizi, Sabrillah Echiguer, Oussama Ssouni, Ayman El Fassi, Abdelilah Ghannam, Zakaria Houssain Belkhadir and Brahim El Ahmadi
Cancers 2025, 17(22), 3687; https://doi.org/10.3390/cancers17223687 - 18 Nov 2025
Abstract
Background: Cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) remains the standard of care for peritoneal surface malignancies but carries significant postoperative risks. In low- and middle-income countries (LMICs), the challenge is magnified by limited access to high-cost enhanced recovery
[...] Read more.
Background: Cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) remains the standard of care for peritoneal surface malignancies but carries significant postoperative risks. In low- and middle-income countries (LMICs), the challenge is magnified by limited access to high-cost enhanced recovery programs. The SCODA (Surgical Complication Optimization through Diet and Activity) program was developed as a low-cost prehabilitation intervention to improve outcomes in resource-constrained settings. Methods: This retrospective cohort study included 169 patients undergoing CRS ± HIPEC at a single academic center in Morocco between 2015 and 2023. Patients treated before SCODA implementation (pre-SCODA group, n = 83) were compared to those enrolled in the SCODA program (SCODA group, n = 86). SCODA included oral iron supplementation, a protein-rich food-based diet, and progressive walking sessions over 90 days. Perioperative outcomes, including pulmonary complications, major morbidity (Clavien–Dindo ≥ 3b), transfusions, ICU stay >3 days, and 90-day mortality, were analyzed using univariate and multivariate logistic regression models. Results: The SCODA group had significantly fewer pulmonary complications (2% vs. 13%, p = 0.008), reduced major morbidity (9% vs. 21%, p = 0.031), fewer transfusions (8% vs. 20%, p = 0.024), and shorter ICU stays (median 1.5 vs. 5 days, p < 0.001). Ninety-day mortality was also lower in the SCODA group (5.8% vs. 12.4%, p = 0.046). SCODA participation remained an independent protective factor in multivariate analyses for all endpoints except major complications. Conclusions: The SCODA program is a feasible and effective prehabilitation strategy for improving surgical outcomes after CRS/HIPEC in LMICs. Its low-cost, food-based, and activity-centered design may support broader implementation in resource-limited environments and inform future perioperative care policies in oncology.
Full article
(This article belongs to the Special Issue Advances in Abdominal Surgical Oncology and Intraperitoneal Therapies)
►▼
Show Figures

Figure 1
Open AccessReview
Elastic Cytomatrix Dynamics Influences Metabolic Rate and Tumor Microenvironment Formation
by
Tattym E. Shaiken, Tulendy T. Nurkenov, Meruyert S. Kurmanbayeva and David Y. Graham
Cancers 2025, 17(22), 3686; https://doi.org/10.3390/cancers17223686 - 18 Nov 2025
Abstract
In healthy cells, the cytomatrix mechanics utilize mitochondrial respiration to control cytosolic motion and fine-tune the chemical processes. In cancer, the cytosolic motion is energized by glycolytic fermentation (the Warburg effect), which provides additional energy to supply the needs of the cytomatrix. Here,
[...] Read more.
In healthy cells, the cytomatrix mechanics utilize mitochondrial respiration to control cytosolic motion and fine-tune the chemical processes. In cancer, the cytosolic motion is energized by glycolytic fermentation (the Warburg effect), which provides additional energy to supply the needs of the cytomatrix. Here, we describe the physical and chemical processes of the integrated and cooperative cytomatrix cytoarchitecture, in which structure and function are inseparable. The extracellular matrix is interconnected with the intracellular cytomatrix and functions as two integrated elastic solid phases. This finding led us to propose mechanisms of tumor microenvironment formation resulting from the mutational burden, in which altered proteins with corresponding post-translational modifications translocate to the cell surface, where they attract immunocompetent cells and activated fibroblasts, producing a tumor-insulating niche. This insulation disrupts cell-to-cell recognition and other signaling pathways that affect the intracellular cytomatrix, particularly actin dynamics, which influence both cell size and shape, recognized as the dedifferentiated state of cancer cells. We also discuss the perspectives of AI in cytomatrix modeling and neural network modeling, focusing on the effects of intracellular and extracellular matrices on the development of the tumor microenvironment.
Full article
(This article belongs to the Section Tumor Microenvironment)
►▼
Show Figures

Graphical abstract
Open AccessSystematic Review
Radical Prostatectomy Following Holmium Laser Enucleation of the Prostate (HoLEP): A Systematic Review of Perioperative, Oncological, and Functional Outcomes
by
Stamatios Katsimperis, Lazaros Tzelves, Titos Markopoulos, Themistoklis Bellos, Konstantinos Douroumis, Nikolaos Kostakopoulos and Andreas Skolarikos
Cancers 2025, 17(22), 3685; https://doi.org/10.3390/cancers17223685 - 18 Nov 2025
Abstract
Background: The widespread adoption of holmium laser enucleation of the prostate (HoLEP) has led to a growing number of men subsequently diagnosed with localized prostate cancer requiring radical prostatectomy (RP). However, anatomical alterations after HoLEP may increase surgical complexity and affect outcomes.
[...] Read more.
Background: The widespread adoption of holmium laser enucleation of the prostate (HoLEP) has led to a growing number of men subsequently diagnosed with localized prostate cancer requiring radical prostatectomy (RP). However, anatomical alterations after HoLEP may increase surgical complexity and affect outcomes. This systematic review aimed to synthesize current evidence on perioperative, oncological, and functional outcomes of RP following HoLEP. Methods: A systematic literature search was conducted in PubMed, CENTRAL, and ClinicalTrials.gov through to September 2025 in accordance with PRISMA 2020 guidelines (PROSPERO CRD420251134483). Eligible studies included patients undergoing RP after HoLEP with reported perioperative, oncologic, or functional data. Methodological quality was assessed using the ROBINS-I tool, and results were synthesized narratively. Results: Eight retrospective studies comprising 202 patients were included. RP after HoLEP was technically feasible across open, laparoscopic, and robotic approaches. Operative time and the need for bladder-neck reconstruction were increased, reflecting post-enucleation fibrosis, but major complication rates (<5%) and blood loss were comparable to primary RP. Oncological outcomes were preserved, with positive surgical margin rates of 6–20% and biochemical recurrence rates of 7–15%, similar to those of primary RP. Functional recovery, particularly urinary continence, was slower initially but generally equivalent at 12 months. Erectile function outcomes were variable but satisfactory when nerve-sparing was feasible. Conclusions: Radical prostatectomy after HoLEP is a technically demanding yet safe procedure that achieves oncologic and long-term functional outcomes comparable to primary prostatectomy. Prior HoLEP should not preclude curative surgical management of prostate cancer, provided the operation is performed by experienced surgeons in high-volume centers.
Full article
(This article belongs to the Special Issue Advances in the Diagnosis and Treatment of Prostate Cancer: From Biomarkers to Precision Surgery)
►▼
Show Figures

Figure 1
Open AccessArticle
Outcomes Following Treatment with Notched Proton Beams for Peripapillary Choroidal Melanomas
by
Gulmeena Hussain, Jonathan Lam, Antonio Eleuteri, Linda Mortimer, Andrzej Kacperek, Bertil Damato, Heinrich Heimann and Rumana Hussain
Cancers 2025, 17(22), 3684; https://doi.org/10.3390/cancers17223684 - 18 Nov 2025
Abstract
Purpose: Peripapillary choroidal melanoma provides a unique challenge; proximity to visually important structures, such as the optic disc and fovea, confers a high risk for the development of maculopathy and optic neuropathy, leading to poorer visual outcomes with most forms of radiotherapy. Ocular
[...] Read more.
Purpose: Peripapillary choroidal melanoma provides a unique challenge; proximity to visually important structures, such as the optic disc and fovea, confers a high risk for the development of maculopathy and optic neuropathy, leading to poorer visual outcomes with most forms of radiotherapy. Ocular proton therapy (OPT) requires an aperture to shape the beam to the tumour. An aperture ‘notch’ may minimise damage to the optic disc and/or the fovea. This study aims to explore if there are any additional advantages to incorporating a notch over the optic nerve beam area. Design: Retrospective audit (cohort study). Participants: Participants included eighty-three patients treated at Liverpool with proton beam therapy from January 2012 to March 2020 for their peripapillary choroidal melanoma. All had a minimum of two and a half years of follow-up vision data; this was to ensure there was enough visual acuity assessment data to perform sufficient analysis. Patients excluded had choroidal melanoma situated over 3 mm from the optic disc, as these were unlikely to have an aperture notch. Methods: A retrospective audit was undertaken in accordance with the Declaration of Helsinki, and registered with the Royal Liverpool Hospitals audit department (audit reference number: Ophth/SE/2024-25/25). Data was collated from the Liverpool Ocular Oncology database, clinic letters and the individual proton beam 3D plans. Robust statistical analysis using a mixed effects model was used to explore associations between notched beams and vision loss and complications. Main Outcome Measures: The primary outcome measure is visual acuity loss post-proton beam therapy. Secondary outcome measures were enucleation and other complication rates. Results: Analysis shows that at 10 years post-OPT, there would be an expected 0.058 (p = 0.077) logMAR of vision saved using a notch for the optic disc compared to no notch (normal apertures); this is considered clinically significant. This cohort also loses vision at a slower rate than other cases. No other predictors were found to be statistically significant for loss of vision, and notched beams showed no advantage in reducing rates of complications. Conclusions: There is some evidence of a trend that utilising a notch for optic disc does show long-term vision benefit; it demonstrates a clinically significant benefit in patients with peripapillary choroidal melanoma.
Full article
(This article belongs to the Section Cancer Therapy)
►▼
Show Figures

Figure 1
Open AccessSystematic Review
Is Nutritional Ultrasound as Useful and Accurate as Computed Tomography to Assess Sarcopenia in Cancer Patients? A Systematic Review
by
Luis M. Luengo-Pérez, Claudia García-Lobato, Lucía Lázaro-Martín, Juan D. Gallardo-Sánchez and Marta M. Guijarro-Chacón
Cancers 2025, 17(22), 3683; https://doi.org/10.3390/cancers17223683 - 18 Nov 2025
Abstract
Background: Sarcopenia assessment provides significant prognostic information that outperforms body mass index and will help to guide interventions to optimize survival outcomes in cancer patients. Computed tomography (CT) is an opportunistic tool used for the assessment of low muscle mass criteria of sarcopenia
[...] Read more.
Background: Sarcopenia assessment provides significant prognostic information that outperforms body mass index and will help to guide interventions to optimize survival outcomes in cancer patients. Computed tomography (CT) is an opportunistic tool used for the assessment of low muscle mass criteria of sarcopenia in cancer patients, while nutritional ultrasound (NU) cutoff points for sarcopenia have been recently proposed. The objective of the present review is to evaluate if NU has a comparable accuracy as CT for the assessment of sarcopenia in cancer patients and could be useful in clinical setting. Methods: Systematic review was registered in Open Science Framework. PubMed and Scopus databases were searched in May and updated in August 2025. All published studies in which patients were evaluated using only one of the previously mentioned modalities, or those involving subjects with non–cancer-related pathologies, were excluded. Two reviewers independently evaluated the risk of bias of selected studies with the National Institutes of Health (NIH) Quality Assessment Tools, and results are presented following the PRISMA 2020 model for systematic reviews. Results: Six studies comprising a total of 1011 patients (57.27% male) were evaluated. Accuracy, variability, and agreement between NU and CT are presented. Conclusions: Main limitations of the evidence include the heterogeneity among studies and their risk of bias. Nevertheless, NU can be a useful tool for sarcopenia diagnosis and can provide a closer and a more flexible follow-up in cancer patients than CT.
Full article
(This article belongs to the Special Issue Clinical Applications of Ultrasound in Cancer Imaging and Treatment)
►▼
Show Figures

Figure 1
Open AccessArticle
Metabolic Syndrome Fuels Genomic Instability? Insights from a Pilot Study on Colorectal Cancer
by
Salvatore Pezzino, Maria Cristina Scuderi, Ornella Coco, Tonia Luca, Gaetano Magro, Mariacarla Castorina, Stefano Puleo and Sergio Castorina
Cancers 2025, 17(22), 3682; https://doi.org/10.3390/cancers17223682 - 18 Nov 2025
Abstract
Background/Objectives: Metabolic syndrome (MS) impacts 25% of the adult population worldwide and elevates the risk of colorectal cancer by 40%. Microsatellite instability (MSI) resulting from impaired DNA mismatch repair serves as a critical biomarker for selecting patients for immunotherapy. Methods: This single-center pilot
[...] Read more.
Background/Objectives: Metabolic syndrome (MS) impacts 25% of the adult population worldwide and elevates the risk of colorectal cancer by 40%. Microsatellite instability (MSI) resulting from impaired DNA mismatch repair serves as a critical biomarker for selecting patients for immunotherapy. Methods: This single-center pilot study examined the correlations between MS and MSI in 157 individuals with surgically treated colorectal cancer. Patients were categorized according to the International Diabetes Federation Metabolic Syndrome criteria. The MSI status was assessed using immunohistochemical investigation of mismatch repair proteins. The statistical analysis encompassed chi-square tests and the computation of odds ratios. Results: Patients with MS exhibited a substantially greater prevalence of MSI compared to controls (15.5% vs. 9.8%, p < 0.05) corresponding to a 1.63-fold increase in odds. The co-occurrence of MSI and hepatic steatosis displayed a strong association within the MS group (OR: 5.81), indicating a 2.6-fold increased prevalence relative to controls. Conclusions: This pilot investigation offers initial evidence associating MS with a heightened frequency of MSI in colorectal cancer. The strong association with hepatic steatosis indicates common metabolic-genomic pathways. The findings advocate for the incorporation of metabolic assessment into precision oncology for the selection of immunotherapy, necessitating multicenter validation studies.
Full article
(This article belongs to the Section Cancer Informatics and Big Data)
►▼
Show Figures

Figure 1
Open AccessReview
Immune Checkpoint Blockade Therapy for Advanced Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patients, Transplant Recipients, and Individuals with Hereditary Syndromes: A Narrative Review
by
Marta Pabianek, Aleksandra Lesiak, Joanna Narbutt, Branka Marinovic and Magdalena Ciazynska
Cancers 2025, 17(22), 3681; https://doi.org/10.3390/cancers17223681 - 17 Nov 2025
Abstract
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer, with incidence steadily increasing due to cumulative ultraviolet (UV) exposure, impaired immune surveillance, and chronic tissue damage. While most cases are effectively managed with surgical excision, a subset progress to locally
[...] Read more.
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer, with incidence steadily increasing due to cumulative ultraviolet (UV) exposure, impaired immune surveillance, and chronic tissue damage. While most cases are effectively managed with surgical excision, a subset progress to locally advanced or metastatic disease, associated with high recurrence rates, limited curative options, and poor prognosis. The introduction of immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis has significantly altered the management of advanced cSCC. Cemiplimab and pembrolizumab are now established systemic therapies, producing durable responses in a proportion of patients. These outcomes reflect the typically high tumor mutational burden and immunogenic microenvironment of cSCC. However, therapeutic decision-making remains particularly complex in several high-risk populations, including solid organ transplant recipients at risk of allograft rejection, patients with chronic dermatologic disorders or non-healing wounds that predispose to carcinogenesis, and individuals with rare hereditary syndromes such as recessive dystrophic epidermolysis bullosa. These so-called challenging populations are frequently excluded from pivotal trials, resulting in limited evidence regarding efficacy, safety, and optimal treatment strategies. This review summarizes current evidence on the management of advanced cSCC in high-risk and underserved patient groups, integrating trial data, real-world evidence, and contemporary guidelines. It also highlights key gaps in knowledge and outlines future directions, with particular focus on the interplay between host immune status, tumor biology, and therapeutic response.
Full article
(This article belongs to the Section Cancer Immunology and Immunotherapy)
Open AccessReview
Rho Small GTPase Family in Androgen-Regulated Prostate Cancer Progression and Metastasis
by
Dontrel William Spencer Hairston, Maria Mudryj and Paramita Mitra Ghosh
Cancers 2025, 17(22), 3680; https://doi.org/10.3390/cancers17223680 - 17 Nov 2025
Abstract
Background/Objectives: Rho small GTPases (RSG), which regulates metastasis, constitute eight subfamilies—“classical” Rho, Rac, cdc42, and “atypical” Rif, Rnd, Wrch, RhoH, and RhoBTB. Their downstream signaling requires switching between GTP-bound active and GDP-bound inactive forms. Classical RSGs, but not atypical RSGs, require regulation
[...] Read more.
Background/Objectives: Rho small GTPases (RSG), which regulates metastasis, constitute eight subfamilies—“classical” Rho, Rac, cdc42, and “atypical” Rif, Rnd, Wrch, RhoH, and RhoBTB. Their downstream signaling requires switching between GTP-bound active and GDP-bound inactive forms. Classical RSGs, but not atypical RSGs, require regulation by guanine nucleotide exchange factors (GEF), GTPase-activating proteins (GAP) and guanine nucleotide dissociation inhibitors (GDI) to achieve this switch. The objective of this review is to summarize the roles of RSGs in metastatic prostate cancer (mPCa) and their interaction with the androgen receptor (AR), which regulates this disease. Methods: We summarize the literature that describes the role of RSGs in mPCa, and their interaction with the AR. Results: Classical RSGs mostly promote metastasis (except RhoB), whereas atypical RSGs, with exceptions, mostly prevent it. Their role, however, is context-dependent—e.g., RhoB is tumor-suppressive in AR-null PCa but oncogenic in AR-positive tumors. The AR modulates RSG expression transcriptionally, but also affects their function through modulation of GEFs, GAPs, and GDIs. In turn, RSGs also regulate AR transcriptional activity. Interestingly, RSGs and the AR have non-genomic interactions via membrane-localized AR (mAR) not affected by AR inhibitors. Conclusions: Drugs that target RSGs are needed along with AR inhibitors to prevent mPCa progression.
Full article
(This article belongs to the Special Issue Advancements in Molecular Research of Prostate Cancer)
►▼
Show Figures

Figure 1
Open AccessArticle
The Preoperative Prognosticators of Surgical Margins (R0 vs. R1) in Pelvic Exenteration—A 14-Year Retrospective Study from a Tertiary Referral Centre
by
Sabina Ioana Nistor, Roman Mykula, Richard Bell, William Gietzmann, Mahmoud Awaly, Alaa Elzarka, Jennifer Thorne, Jacopo Conforti, Federico Ferrari, Nicholas Symons and Hooman Soleymani majd
Cancers 2025, 17(22), 3679; https://doi.org/10.3390/cancers17223679 - 17 Nov 2025
Abstract
Background/Objectives: Pelvic exenteration is a complex surgery considered for locally advanced or recurrent pelvic malignancies, entailing a radical en-block resection of multiple adjacent pelvic organs, followed by reconstructive surgery. Achieving R0 resection (complete removal of macroscopic and microscopic disease) is critical for improving
[...] Read more.
Background/Objectives: Pelvic exenteration is a complex surgery considered for locally advanced or recurrent pelvic malignancies, entailing a radical en-block resection of multiple adjacent pelvic organs, followed by reconstructive surgery. Achieving R0 resection (complete removal of macroscopic and microscopic disease) is critical for improving survival outcomes. This study aimed to define patient, tumour, and surgical predictors of R0 resection in an irradiated field, thereby optimising patient selection and establishing a surgical roadmap for pelvic exenterations. Methods: Our retrospective observational cohort study includes consecutive patients undergoing exenteration post-radiotherapy for non-ovarian gynaecological malignancies at Oxford University Hospitals between 1 January 2011 and 31 December 2024. The primary outcome was margin status. Secondary outcomes were intraoperative and postoperative complications. Results: Twenty-seven patients were identified, with a median age of 63 years (range 41–81) and median BMI of 27 (range 17–45). Primary tumour sites included the vulva (11.1%), vagina (14.8%), cervix (40.7%), and uterus (33.3%). R0 was achieved in 77.8% (n = 21) of cases. Intraoperative complications occurred in 29.6%, and significant postoperative complications (Clavien-Dindo IIIA/IIIB) in 22.2% of patients. R0 resection was significantly associated with younger age (median 61 vs. 70 years, p = 0.035) and primary cervical tumours (p = 0.036). On univariable logistic regression, tumour size on imaging (p = 0.038, OR 2.9) and on histology (p = 0.020, OR 2.01), and estimated blood loss (p = 0.048, OR 1.002) were significant predictors of R0 resection. None of these variables retained significance in multivariable logistic regression. Conclusions: Tumour size, primary tumour site, and patient age should be considered when selecting patients for pelvic exenteration following radiotherapy, and blood loss should be kept minimal in order to maximise the chances of achieving R0 resection.
Full article
(This article belongs to the Section Cancer Therapy)
►▼
Show Figures

Figure 1
Open AccessArticle
Social Burden and Healthcare Costs of Colorectal Cancer
by
Izabela Gąska, Aleksandra Czerw, Monika Pajewska, Olga Partyka, Andrzej Deptała, Anna Badowska-Kozakiewicz, Natalia Czerw, Dominika Mękal, Katarzyna Sygit, Klaudia Malikowska, Jarosław Drobnik, Piotr Pobrotyn, Dorota Waśko-Czopnik, Tomasz Sowiński, Ewa Bandurska, Weronika Ciećko, Elżbieta Grochans, Anna Maria Cybulska, Daria Schneider-Matyka, Kamila Rachubińska, Petre Iltchev, Tomasz Czapla and Remigiusz Kozlowskiadd
Show full author list
remove
Hide full author list
Cancers 2025, 17(22), 3678; https://doi.org/10.3390/cancers17223678 - 17 Nov 2025
Abstract
Background: Colorectal cancer is the third most common malignant cancer, and according to the predictions, the estimated number of new cases will grow in coming years. Therefore, an increase in the costs of the disease will increase as well. Therefore, there is a
[...] Read more.
Background: Colorectal cancer is the third most common malignant cancer, and according to the predictions, the estimated number of new cases will grow in coming years. Therefore, an increase in the costs of the disease will increase as well. Therefore, there is a need for continuous research on the costs and the economic burden of colorectal cancer and for reviewing the research results systematically. The current paper presents a literature review regarding the state of knowledge about the costs of treatment and the economic burden of colorectal cancer. Methods: A total of 20 papers from MEDLINE database were included in the final analysis. The review is focused on the estimates of direct costs, i.e., treatment of colorectal cancer, screening after treatment, and indirect costs. Results: the vast majority of studies were focused on direct costs only, which clearly shows the literature gap. Metastatic colorectal cancer was the most frequent category for various treatment cost evaluation. The costs associated with the use of bevacizumab in various combinations were calculated most frequently. Conclusions: Further summarizing review and developing a methodology for standardized comparisons is necessary, specifically addressing indirect costs.
Full article
(This article belongs to the Special Issue Cost-Effectiveness Studies in Cancers)
►▼
Show Figures

Figure 1
Open AccessArticle
A Comparative Study of Clinical and Molecular Features of Microsatellite Stable Colorectal Cancer With and Without Liver Metastases
by
Tara Magge, Svea Cheng, Shuaichao Wang, Masood Pasha Syed, Bhaghyasree Jambunathan, Ashley Mcfarquhar, Paola Zinser Peniche, Doga Kahramangil Baytar, Aatur Singhi, Anwaar Saeed and Ibrahim Halil Sahin
Cancers 2025, 17(22), 3677; https://doi.org/10.3390/cancers17223677 - 17 Nov 2025
Abstract
Background: The molecular and clinical underpinnings of worse overall survival outcomes with liver metastasis of CRC are not well-defined. We therefore aimed to investigate molecular and clinical characteristics of liver metastasis of CRC in this comparative study. Methods: Patients diagnosed with metastatic CRC
[...] Read more.
Background: The molecular and clinical underpinnings of worse overall survival outcomes with liver metastasis of CRC are not well-defined. We therefore aimed to investigate molecular and clinical characteristics of liver metastasis of CRC in this comparative study. Methods: Patients diagnosed with metastatic CRC from 2014 to 2022 were identified using the institutional molecular database of CRC. Demographic, clinical, and molecular data were collected and analyzed using Fisher’s exact tests for categorical variables, Kaplan–Meier analysis, and multivariate Cox regression analysis. Results: We identified 299 total patients with metastatic CRC, including patients with liver metastasis (n = 205) and non-liver metastasis (n = 94). We observed a significantly higher incidence of liver metastasis among patients with colon cancer compared to rectal cancer (74% vs. 48%, p = 0.00013). There was no significant difference in the incidence of common driver mutations, including KRAS, BRAF, and TP53, in the liver versus non-liver metastasis cohorts. There was a trend toward worse median overall survival among patients with liver metastasis, though this was not statistically significant (42.2 vs. 47.6 months, p = 0.27). Liver metastasis was identified as a significant predictor of shorter time on frontline therapy (HR 1.82, p < 0.001), a surrogate for treatment response, with a median time of 13 months from first- to second-line treatment compared to 19.7 months in the non-liver metastasis cohort (p = 0.00098). KRAS mutations were a significant predictor of worse survival in the liver metastasis cohort only (HR 2.01, p < 0.001), while BRAF mutations were a significant predictor in the non-liver metastasis cohort (HR 3.42, p = 0.006). Conclusions: Liver metastasis of CRC is associated with shorter time on frontline therapy, indicative of potential chemotherapy resistance. Given similar incidence of molecular alterations in patients with liver metastasis and non-liver metastasis, therapeutic resistance may instead be related to the tumor microenvironment of the liver. Most notably, this is the first study to reveal that despite a similar incidence of molecular alterations, driver alterations including BRAF and KRAS mutations may have a distinct impact on survival outcomes depending on the site of metastasis.
Full article
(This article belongs to the Special Issue Recent Advance in Colorectal Cancer Liver Metastases)
►▼
Show Figures

Figure 1
Journal Menu
► ▼ Journal Menu-
- Cancers Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Society Collaborations
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal BrowserHighly Accessed Articles
Latest Books
E-Mail Alert
News
Topics
Topic in
Biomolecules, Cancers, IJMS, Nutrients, Antioxidants
Advances in Adiponectin
Topic Editors: Puran S. Bora, Mayank ChoubeyDeadline: 24 November 2025
Topic in
Cancers, Children, Nutrients
Nutrition and Health During and After Childhood Cancer
Topic Editors: Valérie Marcil, Joya ChandraDeadline: 15 December 2025
Topic in
Cancers, IJERPH, IJGI, MAKE, Smart Cities
The Use of Big Data in Public Health Research and Practice
Topic Editors: Quynh C. Nguyen, Thu T. NguyenDeadline: 31 December 2025
Topic in
Biomolecules, Cancers, Cells, JMP, Livers
Signaling Pathways in Liver Disease 2nd Edition
Topic Editors: Ralf Weiskirchen, Amedeo AmedeiDeadline: 20 March 2026
Conferences
Special Issues
Special Issue in
Cancers
Thyroid Cancer: New Advances from Diagnosis to Therapy: 2nd Edition
Guest Editor: Michael KreißlDeadline: 20 November 2025
Special Issue in
Cancers
Cancer Treatment: Present and Future of Radioligand Therapy
Guest Editors: Egesta Lopci, Akram N. Al-IbraheemDeadline: 20 November 2025
Special Issue in
Cancers
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors (2nd Edition)
Guest Editor: Nuria Romero-LaordenDeadline: 20 November 2025
Special Issue in
Cancers
Aberrant Cytokine Receptor Signaling in Hematological Cancers and Proliferative Disorders
Guest Editor: Alister C. WardDeadline: 20 November 2025
Topical Collections
Topical Collection in
Cancers
Tumor Evolution: Progression, Metastasis and Therapeutic Response
Collection Editor: Theodoros Rampias
Topical Collection in
Cancers
Innovations in Cancer Drug Development Research
Collection Editor: Anupam Bishayee
Topical Collection in
Cancers
Cell Signaling in Cancer and Cancer Therapy
Collection Editors: Zhixiang Wang, Yi Wang
Topical Collection in
Cancers
Treatment of Hepatocellular Carcinoma and Cholangiocarcinoma
Collection Editor: Cristina Mosconi




